The influence of evolutionary landscapes on protective antibody development

进化景观对保护性抗体发育的影响

基本信息

  • 批准号:
    10531875
  • 负责人:
  • 金额:
    $ 47.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-24 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

One of the most pressing issues in modern vaccine development is the poor heterosubtypic neutralizing antibody responses elicited by highly diverse viruses that pose major threats to public health. Elicitation of these so-called broadly neutralizing antibodies (bnAbs) – or antibodies that bind and neutralize many different viral subtypes – are rare in human patients, which complicates vaccine development and allows for repeated annual viral infections (e.g., Influenza and Dengue) or even superinfection (HIV) in human patients. In particular, current vaccines elicit bnAbs at insufficient titers for long-lasting protection against all currently circulating and pandemic Influenza strains. Therefore, it is critical to understand why some Abs are selected over others (i.e., why they are immunodominant), an issue directly relevant to the design of effective vaccines for many recalcitrant infectious diseases. Our long-term objective is to map the development of antibody lineages in a way that enables the prediction of likely responses as a tool to manipulate the process of antibody selection. Our primary objective is to test the hypothesis that the antibody evolutionary landscape is more limited for anti-Influenza bnAbs than for subtype- specific Abs, with this difference explaining why these bnAbs are not often selected at high levels in humans. To test this hypothesis we will display Influenza-specific antibody libraries on yeast and use a transformative sorting and deep sequencing pipeline to evaluate each member variant of the library for its affinity and nonspecific binding properties. This massive functional data will then be used for a network analysis to reconstruct plausible evolutionary trajectories for each somatic bnAb and subtype-specific head Ab. The motivation for the proposed research is guided by the urgent need for develop methods to map and manipulate rules of in vivo antibody affinity maturation to develop vaccines against refractory pathogens of high interest to public health including Influenza, Dengue, and HIV. The proposed research project will be carried out by pursuing three specific aims: 1) Determine ontogeny from germ line to mature human antibodies for two heterosubtypic HA stem binders; 2) Determine ontogeny from germ line to mature human antibodies for four heterosubtypic and subtype- specific HA head binders; 3) Determine the number of evolutionary trajectories from a representative germline Ab. This approach is innovative because it combines a unique hypothesis with state of the art protein engineering tools needed to evaluate the hypothesis, and it is significant because the data generated here will illuminate why long-lasting bnAb responses to HA immunogens are so rare. The approach raised in this application may also expedite rational structure-based design of vaccines, prophylactics, and therapeutics against a range of human pathogens.
现代疫苗发展中最紧迫的问题之一是不良的异亚型中和 由对公众健康构成重大威胁的高度多样化的病毒引起的抗体反应。启发式 这些所谓的广谱中和抗体(BNAbs)--即结合和中和许多不同 病毒亚型-在人类患者中很少见,这使疫苗开发变得复杂,并允许重复 每年人类患者的病毒感染(如流感和登革热)或重叠感染(艾滋病毒)。在……里面 特别是,目前的疫苗诱导的bNAb效价不足,无法持久地预防目前的ALL 流行性和大流行性流感病毒株。因此,了解为什么选择某些抗体是至关重要的 (即为什么它们是免疫优势的),这是一个与有效疫苗设计直接相关的问题 治疗许多顽固不化的传染病。 我们的长期目标是绘制抗体谱系的发展图,以便能够预测 可能的反应作为操纵抗体选择过程的工具。我们的主要目标是测试 假设抗流感bNAbs的抗体进化图景比亚型更有限- 这种差异解释了为什么这些bNAb在人类中通常不是高水平的选择。 为了验证这一假设,我们将在酵母上展示流感特异性抗体库,并使用变型 排序和深度测序流水线,以评估文库的每个成员变体的亲和力和 非特定绑定属性。然后,这些海量的功能数据将用于网络分析 为每个体细胞bNab和亚型特异性头部抗体重建合理的进化轨迹。这个 建议研究的动机是由于迫切需要开发方法来绘制和操纵地图 体内抗体亲和力成熟规则,以开发针对高度感兴趣的难治性病原体的疫苗 公共卫生,包括流感、登革热和艾滋病毒。 拟议的研究项目将通过追求三个具体目标来进行: 1)确定两种异亚型HA干细胞结合蛋白从生殖系到成熟人的个体发育; 2)确定从生殖系到成熟人类的四种异亚型和亚型抗体的个体发育 特定的HA头部粘结剂; 3)确定具有代表性的生殖系Ab的进化轨迹的数目。 这种方法是创新的,因为它结合了一个独特的假说和最先进的蛋白质 需要工程工具来评估假设,这一点很重要,因为这里生成的数据将 解释为什么bNab对HA免疫原的长期反应是如此罕见。在本文中提出的方法 应用还可以加速疫苗、预防和治疗药物的合理结构设计 对抗一系列人类病原体。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Method for User-defined Mutagenesis by Integrating Oligo Pool Synthesis Technology with Nicking Mutagenesis
  • DOI:
    10.21769/bioprotoc.3697
  • 发表时间:
    2020-08-05
  • 期刊:
  • 影响因子:
    0.8
  • 作者:
    Steiner, Paul J.;Baumer, Zachary T.;Whitehead, Timothy A.
  • 通讯作者:
    Whitehead, Timothy A.
Facile Assembly of Combinatorial Mutagenesis Libraries Using Nicking Mutagenesis.
Optimization of multi-site nicking mutagenesis for generation of large, user-defined combinatorial libraries
  • DOI:
    10.1093/protein/gzab017
  • 发表时间:
    2021-02-15
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    Kirby, Monica B.;Medina-Cucurella, Angelica, V;Whitehead, Timothy A.
  • 通讯作者:
    Whitehead, Timothy A.
The importance and future of biochemical engineering
  • DOI:
    10.1002/bit.27364
  • 发表时间:
    2020-05-29
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Whitehead, Timothy A.;Banta, Scott;Wheeldon, Ian
  • 通讯作者:
    Wheeldon, Ian
Standardizing cassette‐based deep mutagenesis by Golden Gate assembly
通过 Golden Gate 组装标准化基于盒的深度诱变
  • DOI:
    10.1002/bit.28564
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Daffern, Nicolas;Francino‐Urdaniz, Irene M.;Baumer, Zachary T.;Whitehead, Timothy A.
  • 通讯作者:
    Whitehead, Timothy A.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Timothy Andrew Whitehead其他文献

Timothy Andrew Whitehead的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Timothy Andrew Whitehead', 18)}}的其他基金

The influence of evolutionary landscapes on protective antibody development
进化景观对保护性抗体发育的影响
  • 批准号:
    10310456
  • 财政年份:
    2019
  • 资助金额:
    $ 47.05万
  • 项目类别:
The influence of evolutionary landscapes on protective antibody development
进化景观对保护性抗体发育的影响
  • 批准号:
    10084802
  • 财政年份:
    2019
  • 资助金额:
    $ 47.05万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 47.05万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 47.05万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 47.05万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.05万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 47.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 47.05万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 47.05万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 47.05万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 47.05万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 47.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了